胸腺肽-α1辅助抗结核2SHR/6HR化疗方案治疗肠结核的效果及对患者免疫功能的影响  

Effect of thymosin-α1 adjuvant anti-tuberculosis 2SHR/6HR chemotherapy regimen in the treatment of intestinal tuberculosis and its influence on immune function of patients

作　　者：韩云 周永 HAN Yun;ZHOU Yong(Shaanxi Tuberculosis Prevention and Control Hospital, Xi'an 710100;Xi'an Chest Hospital, Xi'an 710061, China)

机构地区：[1]陕西省结核病防治院,陕西西安710100 [2]西安市胸科医院,陕西西安710061

出　　处：《临床医学研究与实践》2019年第29期38-40,共3页Clinical Research and Practice

摘　　要：目的观察胸腺肽-α1辅助抗结核2SHR/6HR化疗方案治疗肠结核的效果及对患者免疫功能的影响。方法选取于本院就诊的110例肠结核患者为研究对象,采用奇偶分组法将其分为观察组及参照组,各55例。参照组行抗结核2SHR/6HR化疗方案治疗,观察组行胸腺肽-α1辅助抗结核2SHR/6HR化疗方案治疗。比较两组的临床疗效、治疗前后免疫功能、肠黏膜屏障功能及不良反应发生情况。结果观察组的治疗总有效率为94.55%,高于参照组的69.09%(P<0.05)。治疗后,观察组的NK细胞、CD3^+、CD4^+、CD8^+水平以及CD4^+/CD8^+高于参照组及治疗前,差异有统计学意义(P<0.05)。治疗后,两组的二胺氧化酶、D-乳酸水平均降低,且观察组低于参照组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论胸腺肽-α1辅助抗结核2SHR/6HR化疗方案治疗肠结核可提高治疗效果及患者免疫功能,改善肠黏膜屏障功能,不增加不良反应。Objective To observe the effect of thymosin-α1 adjuvant anti-tuberculosis 2SHR/6HR chemotherapy regimen in the treatment of intestinal tuberculosis and its influence on immune function of patients. Methods A total of 110 cases of intestinal tuberculosis patients treated in our hospital were selected as the research objects. The patients were divided into observation group and reference group by odd-even grouping method, with 55 cases in each group. The reference group was treated with 2SHR/6HR chemotherapy regimen, while the observation group was treated with thymosin-α1 combined with 2SHR/6HR chemotherapy regimen. The clinical efficacy, immune function and intestinal mucosal barrier function before and after treatment, adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group was 94.55%, which was higher than 69.09% in the control group (P<0.05). After treatment, the levels of NK cells, CD3^+, CD4^+, CD8^+ and CD4^+/CD8^+ in the observation group were higher than those in the reference group and before treatment, and the differences were statistically significant (P<0.05). After treatment, the levels of diamine oxidase and D-lactic acid in the two groups decreased, and those in the observation group were lower than the reference group, the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Thymosin-α1 adjuvant anti-tuberculosis 2SHR/6HR chemotherapy regimen in the treatment of intestinal tuberculosis can enhance the therapeutic effect and immune function, and improve intestinal mucosal barrier function, without increasing adverse reactions.

关 键 词：肠结核 2SHR/6HR化疗方案 胸腺肽-Α1 

分 类 号：R524[医药卫生—内科学]